An Open-Label ProSpective MultiCENTer Study to Evaluate Safety and Tolerability of Dry Powder Inhaled Treprostinil in PH (NCT06129240)
An Open-Label ProSpective MultiCENTer Study to Evaluate Safety and Tolerability of Dry Powder Inhaled Treprostinil in Pulmonary Hypertension
🩺 Plain-English Summary (8th-Grade Level)
Study LTI-401 is an open-label, multicenter study which will evaluate the safety and tolerability of LIQ861 in subjects who have WHO Group 1 \& 3 PH.
Who can join: Review the eligibility criteria below.
Location: Arizona Pulmonary Specialists — Phoenix, Arizona
Age range: 18 Years to 80 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (23 Sites)
- Arizona Pulmonary Specialists — Phoenix, Arizona
- The Medical Research Group, Inc. — Fresno, California
- University of California San Diego — La Jolla, California
- UCLA Westwood — Los Angeles, California
- UC Davis — Sacremento, California
- UCSF — San Francisco, California
- National Jewish Health — Denver, Colorado
- Hartford Hospital — Hartford, Connecticut
- Advent Health — Orlando, Florida
- Tampa General Hospital Center of Research Excellence — Tampa, Florida
- Vincent Medical Group — Indianapolis, Indiana
- Norton Pulmonary Specialists — Louisville, Kentucky
- Tufts Medical Center — Boston, Massachusetts
- University of Michigan — Ann Arbor, Michigan
- University of Minnesota — Minneapolis, Minnesota
- NYU Langone Medical Center — New York, New York
- University of Rochester — Rochester, New York
- University of North Carolina at Chapel Hill — Chapel Hill, North Carolina
- University of Cincinnati Health — Cincinnati, Ohio
- Summit Health — Bend, Oregon
- Medical University of South Carolina — Charleston, South Carolina
- Houston Methodist — Houston, Texas
- University of Utah — Salt Lake City, Utah
📞 Contact the Study Coordinator
Phone: (602) 271-0832
Email: nidhi@azpulm.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Pulmonary Hypertension
- Trans-pulmonary Biomarkers in Pulmonary Hypertension — Nashville, Tennessee
- Activity Monitoring in Pulmonary Hypertension — Nashville, Tennessee
- LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF — Tucson, Arizona
- A Study of TX000045 in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction (the APEX Study) — Phoenix, Arizona
- A Study of Mosliciguat in PH-ILD — Phoenix, Arizona
- Frespaciguat (MK-5475) INSIGNIA-PH-COPD: A Study of the Efficacy and Safety of Frespaciguat (an Inhaled sGC Stimulator) in Adults With PH-COPD — San Francisco, California
Explore by condition: All Pulmonary Hypertension clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.